(Q37952923)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Interferons as therapeutic agents for infectious diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

McKenzie C Ferguson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Cathy Santanello

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

Infectious Disease Clinics of North America

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

819-834

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

15 January 2020

cites work

1 reference

12 December 2020

Plantar warts treated with an immune response modifier: a report of two cases

1 reference

12 December 2020

Natural killer cells: primary target for hepatitis C virus immune evasion strategies?

1 reference

12 December 2020

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

1 reference

12 December 2020

Pharmacogenetics of hepatitis C therapy

1 reference

12 December 2020

Long-term interferon-gamma therapy for patients with chronic granulomatous disease

1 reference

12 December 2020

Boceprevir, an NS3 protease inhibitor of HCV.

1 reference

12 December 2020

Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders

1 reference

12 December 2020

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

1 reference

12 December 2020

Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers

1 reference

12 December 2020

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

1 reference

12 December 2020

Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon

1 reference

12 December 2020

Surveillance for acute viral hepatitis - United States, 2007.

1 reference

12 December 2020

Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.

1 reference

12 December 2020

Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1.

1 reference

12 December 2020

The interferon inducing pathways and the hepatitis C virus

1 reference

12 December 2020

Intranasal Lymphoblastoid Interferon ("Well fer on") Prophylaxis Against Rhinovirus and Influenza Virus in Volunteers

1 reference

12 December 2020

Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections

1 reference

12 December 2020

Ribavirin improves early responses to peginterferon through improved interferon signaling

1 reference

12 December 2020

Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers

1 reference

12 December 2020

Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease

1 reference

12 December 2020

A new era of hepatitis C therapy begins

1 reference

12 December 2020

Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families

1 reference

12 December 2020

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

12 December 2020

Snipping away at hepatitis C.

1 reference

12 December 2020

Adjuvant activity of interferon alpha: mechanism(s) of action.

1 reference

12 December 2020

Hepatitis C pharmacogenetics: state of the art in 2010.

1 reference

12 December 2020

Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections.

1 reference

12 December 2020

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

12 December 2020

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds

1 reference

12 December 2020

Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin

1 reference

12 December 2020

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

12 December 2020

Prevention of experimental coronavirus colds with intranasal alpha-2b interferon

1 reference

12 December 2020

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

12 December 2020

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

1 reference

12 December 2020

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

12 December 2020

The interferon inducible gene: Viperin

1 reference

12 December 2020

Interferon for the treatment of genital warts: a systematic review

1 reference

12 December 2020

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

12 December 2020

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

1 reference

12 December 2020

Topical alpha-interferon in recurrent conjunctival papilloma.

1 reference

12 December 2020

Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin

1 reference

12 December 2020

Treatment of focal epithelial hyperplasia with topical imiquimod: report of three cases

1 reference

12 December 2020

Advances in vaccine adjuvants

1 reference

12 December 2020

Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds

1 reference

12 December 2020

The induction of type I interferon production in hepatitis C-infected patients

1 reference

12 December 2020

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients

1 reference

12 December 2020

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

1 reference

12 December 2020

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

1 reference

12 December 2020

A multicenter, randomized, controlled trial of three preparations of low-dose oral alpha-interferon in HIV-infected patients with CD4+ counts between 50 and 350 cells/mm(3). Division of AIDS Treatment Research Initiative (DATRI) 022 Study Group

1 reference

12 December 2020

Tolerance of one-month intranasal interferon

1 reference

12 December 2020

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

1 reference

12 December 2020

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

12 December 2020

Interferons as potential adjuvants in prophylactic vaccines

1 reference

12 December 2020

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation.

1 reference

12 December 2020

Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study

1 reference

12 December 2020

Efficacy of two commercial preparations of interferon-alpha on human papillomavirus replication.

1 reference

12 December 2020

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

1 reference

12 December 2020

Oromucosal interferon therapy: marked antiviral and antitumor activity

1 reference

12 December 2020

Resolution of recurrent conjunctival papilloma after topical and intralesional interferon alpha2b with partial excision in a child.

1 reference

12 December 2020

S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders

1 reference

12 December 2020

Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?

1 reference

12 December 2020

Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment.

1 reference

12 December 2020

Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients

1 reference

12 December 2020

Interferon: mechanisms of action and clinical value

1 reference

12 December 2020

Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin.

1 reference

12 December 2020

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients

1 reference

12 December 2020

Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus

1 reference

12 December 2020

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

12 December 2020

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin.

1 reference

12 December 2020

The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers

1 reference

12 December 2020

Human papillomaviruses and the interferon response

1 reference

12 December 2020

Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.

1 reference

12 December 2020

Intranasal Interferon 2 for Prevention of Rhinovirus Infection and Illness

1 reference

12 December 2020

Interferons at age 50: past, current and future impact on biomedicine

1 reference

12 December 2020

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

12 December 2020

Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds

1 reference

12 December 2020

Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting

1 reference

12 December 2020

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

12 December 2020

Combined antiviral-antimediator treatment for the common cold

1 reference

12 December 2020

Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up.

1 reference

12 December 2020

Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells

1 reference

12 December 2020

Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection

1 reference

12 December 2020

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

12 December 2020

Role of endogenous biological response modifiers in pathogenesis of infectious diseases.

1 reference

12 December 2020

Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults

1 reference

12 December 2020

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin

1 reference

12 December 2020

Alpha 2-interferon for the common cold

1 reference

12 December 2020

10.1016/J.IDC.2011.07.008

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054758%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

1 reference